Andaman7 Argues Case for Greater Patient Mediated Research at HIMSS European Health Conference 2022

Vincent Keunen, CEO and Founder of Andaman7, to share best practice for implementing a patient-centered approach to effectively engage people in the transformation of digital health

‘Data undoubtedly is the golden thread within healthcare, but the challenge lies in promoting willingness to both share, and use health data for primary and secondary use.’ That is the argument for a key session at the 2022 HIMSS European Health Conference, where Vincent Keunen, CEO and Founder of Belgian-American digital health company Andaman7, will participate with other HIMSS Digital Influencers and thought leaders to focus on ‘acceptance, adoption and attitudes towards data sharing, including discussion of the various sources of health data and interoperability, touching on implemented strategies for building trust across all stakeholders; citizens, clinicians, patients and researchers.’

The European conference is part of a wide-ranging response to mitigate the economic and social impact of the coronavirus pandemic, with the EU investing €673bn in “recovery and resilience,” of which at least €13bn targets investment in digital health transformation. Building back stronger and more resilient health systems is the key objective for national digital transformation programs, requiring healthcare and IT leaders to look at greater collaboration across the ecosystem.

Commenting on his participation, Vincent Keunen says:

“Having experience as both a cancer patient and digital health solutions provider, I understand first-hand what is needed, both to shape the future of technology and to improve access to care for patients.

“Disruptive developments such as telemedicine, remote patient monitoring, and interoperability of patient electronic records is shifting power and accountability for healthcare into patients’ hands. Patient mediated research is the next stage – from automated Patient Reported Outcomes (PROs), through Hospital and Patient Health Records (PHR), to Medication Adherence Data for both prescribed and over the counter (OTC) drugs. This additional focus on the use of Real-world data (RWD) and real-world evidence (RWE) will play an increasing role in health care and regulatory decision making, including approval of new indications for approved drugs.”

The session, entitled Building and Maintaining Trust in the use of Health Data will take place Thursday 16 June, 2022 from 10:45-11:45 am   LOCAL TIME Helsinki.

Moderator:  Dr Petra Wilson, (UK). Senior Advisor, European Health Policy & EU Affairs, HIMSS will be speaking with:

  • Mr Vincent Keunen (Belgium) CEO & Founder, Andaman7. Patient advocate.
  • Prof. Sally Lewis (UK) Director of the Welsh Value in Health Centre / National Clinical Lead for Value-Based and Prudent Healthcare, NHS Wales
  • Dr Said Shadi, Chief Digital Officer, Welsh Value in Health Centre, NHS Wales
  • Dr Seemit Dhage Head of Healthcare EMEA, Service Now.

The 2022 HIMSS European Health Conference & Exhibition in Helsinki, Finland, from 14 to 16 June 2022 will cover themes including digital transformation, cybersecurity, interoperability, and data into knowledge.

 

SourceAndaman7

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”